Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry
Neuroendocrine tumors are considered rare tumors: recently an increased incidence and an improvement in survival were described. We explore distribution, incidence and survival of neuroendocrine tumors using population based registry data. We extracted from the Tuscan Cancer Registry neuroendocrine...
Gespeichert in:
| Veröffentlicht in: | Pathology oncology research 2011-09, Vol.17 (3), p.759-763 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 763 |
|---|---|
| container_issue | 3 |
| container_start_page | 759 |
| container_title | Pathology oncology research |
| container_volume | 17 |
| creator | Caldarella, Adele Crocetti, Emanuele Paci, Eugenio |
| description | Neuroendocrine tumors are considered rare tumors: recently an increased incidence and an improvement in survival were described. We explore distribution, incidence and survival of neuroendocrine tumors using population based registry data. We extracted from the Tuscan Cancer Registry neuroendocrine tumors from 1985–2005, and we evaluated distribution, incidence ad survival according to sex, site of tumor, age and stage at diagnosis. 455 cases of neuroendocrine tumors were identified. The overall incidence increased over the study period from 0.7 per 100,000 per year to 1.6 among men (APC +3.6) and from 0.3 to 2.1 among women (APC +4.8). The anatomic distribution of tumors was lung 25.7%, small intestine 23.5%, appendix 10.9%, colon 10.3%, pancreas 9.4%, stomach 7.4%, and rectum 5.2%. Neuroendocrine tumors were more frequent among males and incidence rate increased with age. We observed increased incidence of neuroendocrine tumors, while survival did not change over time. Prognosis varied with age, stage and localization; females had better survival than males. The increase number of neuroendocrine tumors may be due, at least in part, to better registration and to improvement of diagnosis. |
| doi_str_mv | 10.1007/s12253-011-9382-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_884848243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>884848243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-678070382f9442749df9be5191a4ef7afd48289fd5f36891a3a8edd6415010513</originalsourceid><addsrcrecordid>eNp1kU1v3CAQhlGVqvnqD-ilQsqhl7hhMNjQW7v5lKIkatMzYg2siNawAXPwvy-rTaqqUuDAiHnmHYYXoU9AvgIh_VkGSnnbEIBGtoI28zt0ALylDRWk36sxBdkwybt9dJjzE6k1new-oH0KrO-Adgdoc-7zlPyyTD6GU3wTBm9sGOwp1sHghxRXIWafsQ_4zpYUbTBxSD5Y_FjGmPI3rPFD3JS13grgHzpbg39NxczYpTjW7EJXuYR_2tW203yM3ju9zvbjy3mEfl9ePC6um9v7q5vF99tmYG0_NV1fRyB1KCcZoz2Txsml5SBBM-t67QwTVEhnuGs7UW9bLawxHQNOgHBoj9CXne4mxedi86RGnwe7XutgY8lKCFY3ZW0lT_4jn2JJoT5OQV2CcyJZpWBHDSnmnKxTm-RHnWYFRG3dUDs3VHVDbd1Qc635_KJclqM1fytev78CdAfkmgorm_5p_abqH009lKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1111855094</pqid></control><display><type>article</type><title>Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry</title><source>MEDLINE</source><source>SpringerLink_现刊</source><creator>Caldarella, Adele ; Crocetti, Emanuele ; Paci, Eugenio</creator><creatorcontrib>Caldarella, Adele ; Crocetti, Emanuele ; Paci, Eugenio</creatorcontrib><description>Neuroendocrine tumors are considered rare tumors: recently an increased incidence and an improvement in survival were described. We explore distribution, incidence and survival of neuroendocrine tumors using population based registry data. We extracted from the Tuscan Cancer Registry neuroendocrine tumors from 1985–2005, and we evaluated distribution, incidence ad survival according to sex, site of tumor, age and stage at diagnosis. 455 cases of neuroendocrine tumors were identified. The overall incidence increased over the study period from 0.7 per 100,000 per year to 1.6 among men (APC +3.6) and from 0.3 to 2.1 among women (APC +4.8). The anatomic distribution of tumors was lung 25.7%, small intestine 23.5%, appendix 10.9%, colon 10.3%, pancreas 9.4%, stomach 7.4%, and rectum 5.2%. Neuroendocrine tumors were more frequent among males and incidence rate increased with age. We observed increased incidence of neuroendocrine tumors, while survival did not change over time. Prognosis varied with age, stage and localization; females had better survival than males. The increase number of neuroendocrine tumors may be due, at least in part, to better registration and to improvement of diagnosis.</description><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.1007/s12253-011-9382-y</identifier><identifier>PMID: 21476126</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Child ; Child, Preschool ; Female ; Humans ; Immunology ; Incidence ; Infant ; Infant, Newborn ; Italy - epidemiology ; Male ; Middle Aged ; Neuroendocrine Tumors - epidemiology ; Neuroendocrine Tumors - mortality ; Oncology ; Pathology ; Prognosis ; Registries - statistics & numerical data ; Sex Factors ; Survival Rate ; Young Adult</subject><ispartof>Pathology oncology research, 2011-09, Vol.17 (3), p.759-763</ispartof><rights>Arányi Lajos Foundation 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-678070382f9442749df9be5191a4ef7afd48289fd5f36891a3a8edd6415010513</citedby><cites>FETCH-LOGICAL-c437t-678070382f9442749df9be5191a4ef7afd48289fd5f36891a3a8edd6415010513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12253-011-9382-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12253-011-9382-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21476126$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caldarella, Adele</creatorcontrib><creatorcontrib>Crocetti, Emanuele</creatorcontrib><creatorcontrib>Paci, Eugenio</creatorcontrib><title>Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry</title><title>Pathology oncology research</title><addtitle>Pathol. Oncol. Res</addtitle><addtitle>Pathol Oncol Res</addtitle><description>Neuroendocrine tumors are considered rare tumors: recently an increased incidence and an improvement in survival were described. We explore distribution, incidence and survival of neuroendocrine tumors using population based registry data. We extracted from the Tuscan Cancer Registry neuroendocrine tumors from 1985–2005, and we evaluated distribution, incidence ad survival according to sex, site of tumor, age and stage at diagnosis. 455 cases of neuroendocrine tumors were identified. The overall incidence increased over the study period from 0.7 per 100,000 per year to 1.6 among men (APC +3.6) and from 0.3 to 2.1 among women (APC +4.8). The anatomic distribution of tumors was lung 25.7%, small intestine 23.5%, appendix 10.9%, colon 10.3%, pancreas 9.4%, stomach 7.4%, and rectum 5.2%. Neuroendocrine tumors were more frequent among males and incidence rate increased with age. We observed increased incidence of neuroendocrine tumors, while survival did not change over time. Prognosis varied with age, stage and localization; females had better survival than males. The increase number of neuroendocrine tumors may be due, at least in part, to better registration and to improvement of diagnosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Humans</subject><subject>Immunology</subject><subject>Incidence</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Italy - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuroendocrine Tumors - epidemiology</subject><subject>Neuroendocrine Tumors - mortality</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Registries - statistics & numerical data</subject><subject>Sex Factors</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kU1v3CAQhlGVqvnqD-ilQsqhl7hhMNjQW7v5lKIkatMzYg2siNawAXPwvy-rTaqqUuDAiHnmHYYXoU9AvgIh_VkGSnnbEIBGtoI28zt0ALylDRWk36sxBdkwybt9dJjzE6k1new-oH0KrO-Adgdoc-7zlPyyTD6GU3wTBm9sGOwp1sHghxRXIWafsQ_4zpYUbTBxSD5Y_FjGmPI3rPFD3JS13grgHzpbg39NxczYpTjW7EJXuYR_2tW203yM3ju9zvbjy3mEfl9ePC6um9v7q5vF99tmYG0_NV1fRyB1KCcZoz2Txsml5SBBM-t67QwTVEhnuGs7UW9bLawxHQNOgHBoj9CXne4mxedi86RGnwe7XutgY8lKCFY3ZW0lT_4jn2JJoT5OQV2CcyJZpWBHDSnmnKxTm-RHnWYFRG3dUDs3VHVDbd1Qc635_KJclqM1fytev78CdAfkmgorm_5p_abqH009lKg</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Caldarella, Adele</creator><creator>Crocetti, Emanuele</creator><creator>Paci, Eugenio</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry</title><author>Caldarella, Adele ; Crocetti, Emanuele ; Paci, Eugenio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-678070382f9442749df9be5191a4ef7afd48289fd5f36891a3a8edd6415010513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Humans</topic><topic>Immunology</topic><topic>Incidence</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Italy - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuroendocrine Tumors - epidemiology</topic><topic>Neuroendocrine Tumors - mortality</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Registries - statistics & numerical data</topic><topic>Sex Factors</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caldarella, Adele</creatorcontrib><creatorcontrib>Crocetti, Emanuele</creatorcontrib><creatorcontrib>Paci, Eugenio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caldarella, Adele</au><au>Crocetti, Emanuele</au><au>Paci, Eugenio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry</atitle><jtitle>Pathology oncology research</jtitle><stitle>Pathol. Oncol. Res</stitle><addtitle>Pathol Oncol Res</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>17</volume><issue>3</issue><spage>759</spage><epage>763</epage><pages>759-763</pages><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>Neuroendocrine tumors are considered rare tumors: recently an increased incidence and an improvement in survival were described. We explore distribution, incidence and survival of neuroendocrine tumors using population based registry data. We extracted from the Tuscan Cancer Registry neuroendocrine tumors from 1985–2005, and we evaluated distribution, incidence ad survival according to sex, site of tumor, age and stage at diagnosis. 455 cases of neuroendocrine tumors were identified. The overall incidence increased over the study period from 0.7 per 100,000 per year to 1.6 among men (APC +3.6) and from 0.3 to 2.1 among women (APC +4.8). The anatomic distribution of tumors was lung 25.7%, small intestine 23.5%, appendix 10.9%, colon 10.3%, pancreas 9.4%, stomach 7.4%, and rectum 5.2%. Neuroendocrine tumors were more frequent among males and incidence rate increased with age. We observed increased incidence of neuroendocrine tumors, while survival did not change over time. Prognosis varied with age, stage and localization; females had better survival than males. The increase number of neuroendocrine tumors may be due, at least in part, to better registration and to improvement of diagnosis.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>21476126</pmid><doi>10.1007/s12253-011-9382-y</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1219-4956 |
| ispartof | Pathology oncology research, 2011-09, Vol.17 (3), p.759-763 |
| issn | 1219-4956 1532-2807 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_884848243 |
| source | MEDLINE; SpringerLink_现刊 |
| subjects | Adolescent Adult Age Factors Aged Aged, 80 and over Biomedical and Life Sciences Biomedicine Cancer Research Child Child, Preschool Female Humans Immunology Incidence Infant Infant, Newborn Italy - epidemiology Male Middle Aged Neuroendocrine Tumors - epidemiology Neuroendocrine Tumors - mortality Oncology Pathology Prognosis Registries - statistics & numerical data Sex Factors Survival Rate Young Adult |
| title | Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T18%3A14%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distribution,%20Incidence,%20and%20Prognosis%20in%20Neuroendocrine%20Tumors:%20a%20Population%20Based%20Study%20from%20a%20Cancer%20Registry&rft.jtitle=Pathology%20oncology%20research&rft.au=Caldarella,%20Adele&rft.date=2011-09-01&rft.volume=17&rft.issue=3&rft.spage=759&rft.epage=763&rft.pages=759-763&rft.issn=1219-4956&rft.eissn=1532-2807&rft_id=info:doi/10.1007/s12253-011-9382-y&rft_dat=%3Cproquest_cross%3E884848243%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1111855094&rft_id=info:pmid/21476126&rfr_iscdi=true |